View Cart  

Warning to Costa Rican Hospira Plant Hints at Bigger Problems, Analysts Say

An FDA warning letter issued to Hospira’s infusion pump plant in Costa Rica may be emblematic of broader companywide manufacturing issues, analysts say.

To View This Article:


Subscribe To The GMP Letter

Buy This Article Now

Add this article to your cart for $40.00